Trichostatin A, histone deacetylase inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Histone deacetylases collectively known as HDACs include the enzymes HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 and HDAC11. These proteins remove acetyl groups from histone proteins influencing chromatin structure and gene expression. HDAC1 for example has a molecular mass of approximately 55 kDa and is highly expressed in the nucleus of cells where it modifies chromatin architecture. The activity of these enzymes is tightly regulated and they often act as part of multi-subunit complexes to ensure precise control over transcription.

Biological function summary

HDACs play important roles in the regulation of gene expression by modifying the acetylation status of histones. They are integral parts of larger protein complexes such as the Sin3 complex or the NuRD complex which mediate interactions with chromatin to repress transcription. Through these complexes HDACs contribute to cell cycle regulation differentiation and apoptosis. The balance between acetylation and deacetylation maintained by HDACs and histone acetyltransferases (HATs) is critical for normal cellular function.

Pathways

These enzymes are essential in signaling and regulatory networks such as the Notch and p53 pathways. HDAC1 for instance interacts with the p53 protein to regulate cell cycle arrest and apoptosis. In the Notch signaling pathway HDACs participate in the regulation of cell fate determination. Their activity in these pathways often involves collaboration with other proteins including co-repressor proteins to exert their biological effects.

The dysregulation of HDAC activity has been associated with cancer and neurodegenerative diseases. In cancers such as leukemia aberrant HDAC1 activity can lead to uncontrolled cell proliferation due to the repression of tumor suppressor genes. In neurodegenerative conditions like Alzheimer's disease irregular HDAC6 function affects neuronal cell death and cognitive deficits. The therapeutic targeting of HDACs with inhibitors like SAHA (vorinostat) has shown promise in modulating these diseases highlighting the importance of HDACs as drug targets.